Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus
Abstract
:1. Introduction
2. Quadrivalent Vaccine
2.1. Preparation
2.2. Phase I Safety Data/Results
2.3. Phase II
2.3.1. Safety
2.3.2. Efficacy
2.4. Phase III
2.4.1. Safety
2.4.2. Efficacy
2.5. FDA Approval
2.6. Further Data from Clinical Trials
3. Bivalent Vaccine
3.1. Preparation
3.2. Phase I Safety Data/Results
3.3. Phase II
3.3.1. Safety
3.3.2. Efficacy
3.4. Phase III
3.4.1. Safety
3.4.2. Efficacy
3.5. FDA Approval
3.6. Further Data from Clinical Trials
3.7. Comparison with Quadrivalent Vaccine
4. Investigational Vaccines
4.1. Multivalent Vaccine
4.2. L2 Vaccine
4.3. Therapeutic HPV Vaccine
5. Conclusions
Supplementary Files
Supplementary File 1Acknowledgments
Author Contributions
Conflicts of Interest
References
- Crosbie, E.J.; Einstein, M.H.; Franceschi, S.; Kitchener, H.C. Human papillomavirus and cervical cancer. Lancet 2013, 382, 889–899. [Google Scholar] [CrossRef] [PubMed]
- Sand, L.; Jalouli, J. Viruses and oral cancer. Is there a link? Microbes Infect. 2014, 16, 371–378. [Google Scholar] [CrossRef]
- Markopoulos, A.K. Role of human papillomavirus in the pathogenesis of oral squamous cell carcinoma. World J. Exp. Med. 2012, 2, 65–69. [Google Scholar] [CrossRef] [PubMed]
- Cardoso, J.C.; Calonje, E. Cutaneous manifestations of human papillomaviruses: A review. Acta Dermatoven APA 2011, 20, 145–154. [Google Scholar]
- Bruni, L.; Diaz, M.; Castellsague, X.; Ferrer, E.; Bosch, F.X.; de Sanjosé, S. Cervical Human Papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. JID 2010, 202, 1789–1799. [Google Scholar] [CrossRef] [PubMed]
- Tommasino, M.; Accardi, R.; Caldeira, S.; Dong, W.; Malanchi, I.; Smet, A.; Zehbe, I. The role of TP53 in cervical carcinogenesis. Hum. Mutat. 2003, 21, 307–312. [Google Scholar] [CrossRef] [PubMed]
- Munger, K.; Basile, J.R.; Duensing, S.; Eichten, A.; Gonzalez, S.L.; Grace, M.; Zacny, V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20, 7888–7898. [Google Scholar] [CrossRef] [PubMed]
- Dunner, E.F.; Unger, E.R.; Sternberg, M.; McQuillan, G.; Swan, D.C.; Patel, S.S.; Markowitz, L.E. Prevalence of HPV infection among females in the United States. JAMA 2007, 297, 813–819. [Google Scholar] [CrossRef] [PubMed]
- Forman, D.; de Martel, C.; Lacey, C.J.; Soerjomatarm, I.; Lortet-Tieulent, J.; Bruni, L.; Vignat, J.; Ferley, J.; Bray, F.; Plummer, M. Global burden of Human Papillomavirus and related diseases. Vaccine 2012, 30. [Google Scholar] [CrossRef] [PubMed]
- Tota, J.E.; Chevarie-Davis, M.; Richardson, L.A.; Devries, M.; Franco, E.L. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prevent. Med. 2011, 53 (Suppl. S1), 12–21. [Google Scholar] [CrossRef]
- Barr, E.; Tamms, G. Quadrivalent human papillomavirus vaccine. Clin. Infect. Dis. 2007, 45, 609–607. [Google Scholar] [CrossRef] [PubMed]
- Schmiedeskamp, M.R.; Kockler, D.R. Human papillomavirus vaccines. Ann. Pharmacother. 2006, 40, 1344–1352. [Google Scholar] [CrossRef] [PubMed]
- Stanley, M. Immune responses to human papillomavirus. Vaccine 2006, 24 (Suppl. S1), 16–22. [Google Scholar] [CrossRef]
- Ault, K.A.; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomized clinical trials. Lancet 2007, 369, 1861–1868. [Google Scholar]
- U.S. Food and Drug Administration. VRBPAC Background Document: Gardasil HPV Quadrivalent Vaccine. Available online: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf (accessed on 24 September 2014).
- Garland, S.M.; Hernandez-Avila, M.; Wheeler, C.M.; Perez, G.; Harper, D.M.; Leodolter, S.; Tang, G.W.; Ferris, D.G.; Steben, M.; Bryan, J. Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. N. Engl. J. Med. 2007, 356, 1928–1943. [Google Scholar] [CrossRef] [PubMed]
- The FUTURE II Study Group. Quadrivalent vaccine against human papilloma virus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356, 1915–1927. [Google Scholar]
- Paavonen, J.; Naud, P.; Salmeron, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.; Kitchener, H.; Castellasague, X.; Teixeira, J.C.; Skinner, S.R. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind randomized study in young women. Lancet 2009, 374, 301–314. [Google Scholar] [CrossRef] [PubMed]
- Mao, C.; Koutsky, L.A.; Ault, K.A.; Wheeler, C.M.; Brown, D.R.; Wiley, D.J.; Alvarez, F.B.; Bautista, O.M.; Jansen, K.U.; Barr, E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet. Gynecol. 2006, 107, 18–27. [Google Scholar] [CrossRef] [PubMed]
- Harper, D.M.; Franco, E.L.; Wheeler, C.M.; Moscicki, A.B.; Romanowski, B.; Roteli-Martins, C.M.; Jenkins, D.; Schuind, A.; Costa Clemens, S.A.; Dubin, G. Sustained efficacy up to 4.5 years of a bivalent L2 virus-like particle vaccine against human papillomavirus types 16 and 18, follow-up from a randomized controlled trial. Lancet 2006, 367, 1247–1255. [Google Scholar]
- Harper, D.; Gall, S.; Naud, P.; Quint, W.; Dubin, G.; Jenkins, D. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix (GSK’s HPV 16/18 AS04 candidate vaccine). In Proceedings of the 39th Annual Meeting on Women’s Cancer of the Society of Gynecologic Oncologists, Tampa, FL, USA, 9–12 March 2008.
- Villa, L.L.; Costa, R.L.; Petta, C.A.; Andrade, R.P.; Ault, K.A.; Giuliano, A.R.; Wheeler, C.M.; Koutsky, L.A.; Malm, C.; Lehtinen, M. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6, 271–278. [Google Scholar] [CrossRef] [PubMed]
- Villa, L.L.; Costa, R.L.; Petta, C.A.; Andrade, R.P.; Paavonen, J.; Iversen, O.E.; Olsson, S.E.; Hoye, J.; Steinwall, M.; Riis-Johannessen, G. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 year of follow-up. Br. J. Cancer 2006, 95, 1459–1466. [Google Scholar] [CrossRef] [PubMed]
- Julius, J.M.; Ramondeta, L.; Tipton, K.A.; Lal, L.S.; Schneider, K.; Smith, J.A. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy 2011, 31, 280–297. [Google Scholar] [CrossRef] [PubMed]
- The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J. Infect. Dis. 2007; 196, 1438–1446. [Google Scholar]
- Olsson, S.E.; Villa, L.L.; Costa, R.L.; Petta, C.A.; Andrade, R.P.; Malm, C.; Iversen, O.E.; Hoye, J.; Steinwall, M.; Riis-Johannessen, G. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25, 4931–4939. [Google Scholar] [CrossRef] [PubMed]
- Sattler, C.; UTURE I Investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) LI virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). In Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 16–19 December 2005; American Society for Microbiology: Washington, DC, USA.
- Merck & Co., Inc. Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant suspension for intramuscular injection) product information. Whitehouse Station: NJ, USA, 2009. [Google Scholar]
- U.S. Food and Drug Administration. FDA approves new indication for Gardasil to prevent genital warts in men and boys, October 16, 2009. Available online: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucml87003.htm (accessed on 25 September 2014).
- Brotheron, J.M.; Fridman, M.; May, C.L.; Chappell, G.; Saville, A.M.; Gertig, D.M. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011, 377, 2085–2092. [Google Scholar] [CrossRef] [PubMed]
- Crowe, E.; Pandeya, N.; Brotherton, J.M.; Dobson, A.J.; Kisely, S.; Lambert, S.B.; Whiteman, D.C. Effectiveness of quadrivalent human papillomavirus vaccine or the prevention of cervical abnormalities: A case-control study nested within a population based screening programme in Australia. BMJ 2014, 348. [Google Scholar] [CrossRef] [PubMed]
- Kahn, J.A.; Brown, D.R.; Ding, L.; Widdice, L.E.; Shew, M.L.; Glynn, S.; Bernstein, D.I. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 130. [Google Scholar] [CrossRef] [PubMed]
- Herweijer, E.; Leval, A.; Ploner, A.; Eloranta, S.; Simard, J.F.; Dillner, J.; Netterlid, E.; Sparén, P.; Arnheim-Dahlström, L. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014, 311, 597–603. [Google Scholar] [CrossRef] [PubMed]
- Giuliano, A.R.; Palefsky, J.M.; Goldstone, S.; Moreira, E.D., Jr.; Penny, M.E.; Aranda, C.; Vardas, E.; Moi, H.; Jessen, H.; Hillman, R. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 2011, 364, 401–411. [Google Scholar]
- Palefsky, J.M.; Giuliano, A.R.; Goldstone, S.; Moreira, E.D., Jr.; Aranda, C.; Jessen, H.; Hillman, R.; Ferris, D.; Coutlee, F.; Stoler, M.H.; Marshall, J.B. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011, 365, 1576–1585. [Google Scholar] [CrossRef] [PubMed]
- Cervarix (Human Papillomavirus Bivalent Vaccine, Recombinant Intramuscular Injection) Product Information; GlaxoSmithKline: Research Triangle Park, NC, USA, 2009.
- U.S. Food and Drug Administration. Memorandum: Clinical Review of Biologics License Application for Human Papillomavirus 16, 18 L1 Virus Like Particle Vaccine, AS04 Adjuvant-Adsorbed (Cervarix). Available online: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm237976.pdf (accessed on 24 September 2014).
- GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski, B.; de Borba, P.C.; Naud, P.S.; Roteli-Martins, C.M.; De Carvalho, N.S.; Teixiera, J.C.; Aoki, F.; Ramjattan, B.; Shier, R.M.; Somani, R. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374, 1975–1985. [Google Scholar]
- Hildesheim, A.; Herrero, R.; Wacholder, S.; Rodriguez, A.C.; Solomon, D.; Bratti, M.C.; Schiller, J.T.; Gonzalez, P.; Dubin, G.; Porras, C. Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: A randomized trial. JAMA 2007, 298, 743–753. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, C.; Petaja, T.; Strauss, G.; Rumke, H.C.; Poder, A.; Richardus, J.H.; Spiessens, B.; Descamps, D.; Hardt, K.; Lehtinen, M.; et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing ASO4 adjuvant. J. Adolesc. Health. 2007, 40, 564–571. [Google Scholar]
- U.S. Food and Drug Administration. News release: FDA approves new vaccine for prevention of cervical cancer, 16 October 2009. Available online: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm187048.htm (accessed on 25 September 2014).
- Angelo, M.G.; Zima, J.; Tavares Da Silva, F.; Baril, L.; Arellano, F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: More than 4 years of experience. Pharmacoepidemiol. Drug Saf. 2014, 23, 456–465. [Google Scholar] [CrossRef] [PubMed]
- Einstein, M.H.; Baron, M.; Levin, M.J.; Chatterjee, A.; Edwards, R.; Zepp, F.; Carletti, I.; Dessy, F.; Trofa, A.; Schuind, A.; et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum. Vaccine 2009, 5, 705–719. [Google Scholar]
- Banura, C.; Mirembe, F.M.; Katahoire, A.R.; Namujju, P.B.; Mbidde, E.K. Universal routine HPV vaccination for young girls in Uganda: A review of opportunities and potential obstacles. Infect. Agent Cancer 2012, 7. [Google Scholar] [CrossRef]
- Merck. FDA approves Merck’s HPV vaccine, GARDASIL 9, to prevent cancers and other diseases caused by nine HPV types—Including types that cause about 90% of cervical cancer cases. 11 December 2014. Available online: http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an (accessed on 5 February 2015).
- Fahey, L.M.; Raff, A.B.; da Silva, D.M.; Kast, W.M. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J. Immunol. 2009, 183, 6151–6156. [Google Scholar] [CrossRef] [PubMed]
- Gambhira, R.; Karanam, B.; Jagu, S.; Roberts, J.N.; Buck, C.B.; Bossis, I.; Alphs, H.; Culp, T.; Christensen, N.D.; Roden, R.B. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 2007, 81, 13927–13931. [Google Scholar] [CrossRef] [PubMed]
- Roden, R.B.; Yutzy, W.H., IV; Fallon, R.; Inglis, S.; Lowy, D.R.; Schiller, J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000, 270, 254–257. [Google Scholar]
- Gambhira, R.; Jagu, S.; Karanam, B.; Gravitt, P.E.; Culp, T.D.; Christensen, N.D.; Roden, R.B. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 2007, 81, 11585–11592. [Google Scholar] [CrossRef] [PubMed]
- Karanam, B.; Gambhira, R.; Peng, S.; Jagu, S.; Kim, D.J.; Ketner, G.W.; Stern, P.L.; Adams, R.J.; Roden, R.B. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009, 27, 1040–1049. [Google Scholar] [CrossRef] [PubMed]
- Gambhira, R.; Gravitt, P.E.; Bossis, I.; Stern, P.L.; Viscidi, R.P.; Roden, R.B. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res. 2006, 66, 11120–11124. [Google Scholar] [CrossRef] [PubMed]
- De Jong, A.; O’Neill, T.; Khan, A.Y.; Kwappenberg, K.M.; Chisholm, S.E.; Whittle, N.R.; Dobson, J.A.; Jack, L.C.; St Clair Roberts, J.A.; Offringa, R. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002, 20, 3456–3464. [Google Scholar] [CrossRef] [PubMed]
- Van der Burg, S.H.; Kwappenberg, K.H.; O’Neill, T.; Brandt, R.M.; Melief, C.J.; Hickling, J.K.; Offringa, R. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001, 9, 3652–3660. [Google Scholar] [CrossRef]
- Campo, M.S.; Roden, R.B. Papillomavirus prophylactic vaccines: Established successes, new therapies. J. Virol. 2010, 84, 1214–1220. [Google Scholar] [CrossRef] [PubMed]
- Schiller, J.T.; Castellsague, X.; Garland, S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30, 123–138. [Google Scholar] [CrossRef]
- Melero, I.; Gaudernack, G.; Gerritsen, W.; Huber, C.; Parmiani, G.; Scholl, S.; Thatcher, N.; Wagstaff, J.; Zielinski, C.; Faulkner, I. Therapeutic vaccines for cancer: An overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11, 509–524. [Google Scholar] [CrossRef] [PubMed]
- Nakagawa, M.; Stites, D.P.; Farhat, S.; Sisler, J.R.; Moss, B.; Kong, F.; Moscicki, A.B.; Palefsky, J.M. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus RYPE 16: Relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 1997, 175, 927–931. [Google Scholar] [CrossRef] [PubMed]
- Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, C.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745. [Google Scholar] [CrossRef] [PubMed]
- Welters, M.J.; Kenter, G.G.; van de Vos Steenwijk, P.J.; Löwik, M.J.; Berends-van der Meer, D.M.; Essahsah, F.; Stynenbosch, L.F.; Vloon, A.P.; Ramwadhdoebe, T.H.; Piersma, S.J. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl. Acad. Sci. USA 2010, 107, 11895–11899. [Google Scholar] [CrossRef] [PubMed]
- Bagarazzi, M.L.; Yan, J.; Morrow, M.P.; Shen, X.; Parker, R.L.; Lee, J.C.; Giffear, M.; Pankhong, P.; Khan, A.S.; Broderick, K.E. Immunotherapy against HPV16/18 generates potent Th1 and cytotoxic cellular immune responses. Sci. Transl. Med. 2012, 4. [Google Scholar] [CrossRef]
- Bae, S.H.; Park, Y.J.; Park, J.B.; Choi, Y.S.; Kim, M.S.; Sin, J.I. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: Causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res. 2007, 13, 341–349. [Google Scholar] [CrossRef] [PubMed]
- Sin, J.I.; Kim, J.M.; Bae, S.H.; Lee, I.H.; Park, J.S.; Ryoo, H.M. Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol. Ther. 2009, 17, 906–913. [Google Scholar] [CrossRef] [PubMed]
- Ye, G.W.; Park, J.B.; Park, Y.J.; Choi, Y.S.; Sin, J.I. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther. 2007, 15, 1564–1570. [Google Scholar] [CrossRef] [PubMed]
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kash, N.; Lee, M.A.; Kollipara, R.; Downing, C.; Guidry, J.; Tyring, S.K. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J. Clin. Med. 2015, 4, 614-633. https://doi.org/10.3390/jcm4040614
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. Journal of Clinical Medicine. 2015; 4(4):614-633. https://doi.org/10.3390/jcm4040614
Chicago/Turabian StyleKash, Natalie, Michael A. Lee, Ramya Kollipara, Christopher Downing, Jacqueline Guidry, and Stephen K. Tyring. 2015. "Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus" Journal of Clinical Medicine 4, no. 4: 614-633. https://doi.org/10.3390/jcm4040614
APA StyleKash, N., Lee, M. A., Kollipara, R., Downing, C., Guidry, J., & Tyring, S. K. (2015). Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. Journal of Clinical Medicine, 4(4), 614-633. https://doi.org/10.3390/jcm4040614